Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

View the 50 largest pharmaceutical companies in the world listings here

Regeneron

Regeneron Pharmaceuticals

Rank: 27

Tarrytown, N.Y., USA
www.regeneron.com

2020 Revenues ($USD) : $8,497,100,000
2020 R&D spend : $2,735,000,000
2020 Number of Employees : 9,123
Fiscal Year End : 12/31/2020
Key People : Leonard Schleifer, CEO and president

Regeneron Pharmaceuticals is a biotechnology company that commercializes medicines designed to treat patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and other rare diseases. The Tarrytown, N.Y.-based company commercializes eight medicines, with its Eylea injection leading sales in its most recent fiscal year. In November last year, Regeneron's antibody cocktail casirivimab and imdevimab received FDA emergency use authorization to treat mild to moderate COVID-19 in adults and pediatric patients at least 12 years of age and weighing at least 40 kg. –DK

Regeneron

Regeneron is headquartered north of New York City in Tarrytown, N.Y.

Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50